

HOMMAGE À JEAN-PHILIPPE COLLET

**APPORT DE L'ÉCOLE DE LA PITIÉ-SALPÊTRIÈRE
EN CARDIOLOGIE INTERVENTIONNELLE**

**F Beygui
CHU Côte de Nacre, Caen**

ARTICLES | VOLUME 384, ISSUE 9354, P1577-1585, NOVEMBER 01, 2014

Download Full Issue

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial

Prof Jean-Philippe Collet, MD • Johanne Silvain, MD • Olivier Barthélémy, MD • Grégoire Rangé, MD •

an Belle, MD • et al. Show all authors • Show footnotes

[https://doi.org/10.1016/S0140-6736\(14\)60612-7](https://doi.org/10.1016/S0140-6736(14)60612-7) • Check for updates

FAST TRACK — ARTICLES | VOLUME 373, ISSUE 9692, P309-317, JANUARY 24, 2009

Download Full Issue

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

Jean-Philippe Collet, MD • Jean-Sébastien Hulot, MD • Anna Pena, PhD • Eric Villard, PhD • Jean-Baptiste Esteve, MD • Johanne Silvain, MD • et al. Show all authors

Bedside Monitoring to Adjust Antiplatelet Therapy for Coronary Stenting

Jean-Philippe Collet, M.D., Ph.D., Thomas Cuisset, M.D., Ph.D., Grégoire Rangé, M.D., Guillaume Cayla, M.D., Ph.D., Simon Elhadad, M.D., Christophe Pouillot, M.D., Patrick Henry, M.D., Ph.D., Pascal Motreff, M.D., Ph.D.,



Journal of the American College of Cardiology
Volume 74, Issue 1, January 14, 2014

Original Investigation

Long-Term Evolution of Coronary Artery Disease

Jean-Philippe Collet MD, PhD^{a,*}, Michel
Jean-Sébastien Hulot MD, PhD^b, Johanne
Daniel Thomas MD^a, Benoit Lattuca MD^c,
Jean-Baptiste Esteve MD^d, Laurent P
Abdourahmane Diallo PhD^e, Eric Vicaire
ACTION Study Group

Circulation

AMA Journals Journal Information All Issues Subjects Features Resources

Home > Circulation > Vol 128, No 12 > Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose

The Reload With Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term With Dual Antiplatelet Therapy (RELOAD) Study

Jean-Philippe Collet, Johanne Silvain, Antoine Landry, Marie-Laure Tangay, Guillaume Cayla, Anne Bellemain, Nicolas Vignolles, Sophie Gallier, Florent Reygan, Ana Fine and Gilles Montalescot

Originally published 2 May 2013; <https://doi.org/10.1161/CIRCULATION.128.117171> | Circulation. 2013;128:1229-1235



Blood. 2005 Dec 1; 106(12): 3824-3830.

Prepublished online 2005 Aug 9. doi: [10.1182/blood-2005-05-2150](https://doi.org/10.1182/blood-2005-05-2150)

The α C domains of fibrinogen affect the structure of the fibrin clot, its physical properties, and its susceptibility to fibrinolysis

Jean-Philippe Collet, Jennifer L. Moen, Yuri I. Veklich, Oleg V. Gorkun, Susan T. Lord, Gilles Montalescot, and John W. Weisel

Journal of the American College of Cardiology

Volume 48, Issue 7, 3 October 2006, Pages 1326-1335



Journal of the American College of Cardiology
Volume 41, Issue 1, 1 January 2003, Pages 8-14

Clinical study: myocardial infarction and acute coronary syndrome

Enoxaparin in unstable angina patients who have been excluded from randomized trials

Gilles Montalescot MD, PhD^{*}, Erika Fine MD^{*},
Gilles Dalby MD^{*}, R.émi Choussat MD^{*}, Annick Ankri MD[†],
Lesty PhD^{*}, Nicolas Vignolles BSc^{*}, Daniel Thomas MD^{*}



Volume 37, Issue 32
21 August 2016

Article Contents

Abstract



Volume 26, Issue 21
November 2005

Article Contents



Volume 39, Issue 3
14 January 2018



Volume 42, Issue 14
7 April 2021

Article Contents

Table of contents

<https://doi.org/10.1093/eurheartj/ehv675>

Published: 26 December 2015

Article history

JOURNAL ARTICLE

Non-ST-segment elevation acute coronary syndrome in patients with renal dysfunction: benefit of low-molecular-weight heparin alone or with glycoprotein IIb/IIIa inhibitors on outcomes. The Global Registry of Acute Coronary Events

Jean-Philippe Collet, Gilles Montalescot, Giancarlo Agnelli, Frans Van de Werf, Enrique P. Gurfinkel, Jose López-Sendón, Christopher V. Laufenberg, Martin Klutman, Neelam Gowda, Dietrich Gulba for the GRACE Investigators

JOURNAL ARTICLE

Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease

Jean-Philippe Collet, Marco Roffi, Robert A Byrne, Francesco Costa, Marco Valgimigli, Task Force for the Management of Dual Antiplatelet Therapy in Coronary Artery Disease of the European Society of Cardiology (ESC)

ESC Scientific Document Group Author Notes

JOURNAL ARTICLE GUIDELINES

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

Jean-Philippe Collet, Holger Thiele, Emanuele Barbato, Olivier Barthélémy, Johann Bauersachs, Deepak L Bhatt, Paul Dendale, Maria Dorobantu, Thor Edvardsen, Thierry Lelloucq, Show more

1999-2002

Circulation

AHA Journals

Journal Information

All Issues

Subjects

Features

Resources & Ed

Home > Circulation > Vol. 103, No. 5 > Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris

FREE ACCESS

OTHER

PDF/EPUB

Percutaneous Coronary Intervention After Subcutaneous Enoxaparin Pretreatment in Patients With Unstable Angina Pectoris

J. Ph. Collet, G. Montalescot, L. Lison, R. Choussat, A. Ankri, G. Drobinski, I. Sotirov and D. Thomas

Originally published 6 Feb 2001 | <https://doi.org/10.1161/01.CIR.103.5.658> | Circulation. 2001;103:658

Arteriosclerosis, Thrombosis, and Vascular Biology

AHA Journals

Journal Information

All Issues

Subjects

Features

Res

Home > Arteriosclerosis, Thrombosis, and Vascular Biology > Vol. 21, No. 1 > Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis

FREE ACCESS

OTHER

PDF/EPUB

Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Exposure and Promotes Fibrinolysis

J. P. Collet, G. Montalescot, C. Lesty, J. Soria, Z. Mishal, D. Thomas and C. Soria

Originally published 1 Jan 2001 | <https://doi.org/10.1161/01.ATV.21.1.142> | Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:142-148

Circulation Research

AHA Journals

Journal Information

All Issues

Subjects

Features

Resources & Ed

Home > Circulation Research > Vol. 90, No. 4 > A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots

FREE ACCESS

OTHER

PDF/EPUB

A Structural and Dynamic Investigation of the Facilitating Effect of Glycoprotein IIb/IIIa Inhibitors in Dissolving Platelet-Rich Clots

J.Ph. Collet, G. Montalescot, C. Lesty and J.W. Weisel

Originally published 17 Jan 2002 | <https://doi.org/10.1161/hh0402.105095> | Circulation Research. 2002;90:428-434

Other version(s) of this article

Tools

Share

Circulation

AHA Journals

Journal Information

All Issues

Subjects

Features

Resources & Ed

Home > Circulation > Vol. 103, No. 19 > Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention

FREE ACCESS

OTHER

PDF/EPUB

Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention

J. P. Collet, G. Montalescot, C. Lesty, Z. Mishal, J. Soria, R. Choussat, G. Drobinski, C. Soria, P. Pinton, P. Barragan and D. Thomas

Originally published 15 May 2001 | <https://doi.org/10.1161/01.CIR.103.19.2328> | Circulation. 2001;103:2328-2331

Arteriosclerosis, Thrombosis, and Vascular Biology

AHA Journals

Journal Information

All Issues

Subjects

Features

Resources & Ed

Home > Arteriosclerosis, Thrombosis, and Vascular Biology > Vol. 20, No. 5 > Influence of Fibrin Network Conformation and Fibrin Fiber Diameter on Fibrinolysis Speed

FREE ACCESS

OTHER

PDF/EPUB

Influence of Fibrin Network Conformation and Fibrin Fiber Diameter on Fibrinolysis Speed

J. P. Collet, D. Park, C. Lesty, J. Soria, G. Montalescot and J. W. Weisel

Originally published 1 May 2000 | <https://doi.org/10.1161/01.ATV.20.5.1354> | Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:1354-1361



Tools


Share

Focus Issue: Cardiac Intervention

Intervention in Acute Coronary Syndrome

Percutaneous Coronary Intervention After Fibrinolysis: A Multiple Meta-Analyses Approach According to the Type of Strategy

Jean-Philippe Collet MD, PhD *, Gilles Montalescot MD, PhD *  , Michel Le May MD †, Maria Borentain MD *, Anthony Gershlick MD ‡





Volume 37, Issue 32
21 August 2016

Article Contents

Abstract

JOURNAL ARTICLE EDITOR'S CHOICE

Registry on acute cardiovascular events during endurance running races: the prospective RACE Paris registry ^{FREE}

Benoît Gerardin, Jean-Philippe Collet ✉, Hazrije Mustafic, Anne Bellemain-Appaix, Hakim Benamer, Jacques Monsegu, Emmanuel Teiger, Bernard Livarek, Murielle Jaffry, Lionel Lamhaut, Catherine Fleischel, Pierre Aubry for the Groupe de Réflexion sur la Cardiologie Interventionnelle

European Heart Journal, Volume 37, Issue 32, 21 August 2016, Pages 2531–2541,
<https://doi.org/10.1093/eurheartj/ehv675>

Published: 26 December 2015 **Article history** ▼

B Lethality according to previous training (<3 marathons vs. ≥3 marathons)

Study name	Statistics for each study				P-Value	Odds ratio and 95% CI	Relative weight
	OR	Lower	<3M Events(total)	≥3M Events(total)			
Maron 1996	3	0.07	115/33	2 (3)	0.555		29.47
Roberts 2005	0.55	0.01	24/51	0 (1)	0.761		27.36
Gerardin 2014	1.20	0.05	24/47	1 (6)	0.906		43.17
	1.27	0.17	9.23	3 (9)	0.811		

Heterogeneity: $I^2 = 0\%$
Egger's regression test for publication bias argument: $P = 0.95$

Lethality according to running race type (marathon vs. semi-marathon)

All studies	Statistics for each study				P-Value	Odds ratio and 95% CI	Relative weight
	OR	95% CI	M. Events(Total)	SM. Events(Total)			
All studies*	1.16	0.26	5.24	5 (15)	0.841		100.00
	1.167	0.26	5.24	5 (15)	0.841		

* Maron 1996, Schwabe 2014, Gerardin 2014
Heterogeneity and Egger's regression test not estimable

A Lethality according to age (< 35 years vs. ≥ 35 years)

Study name	Statistics for each study				P-Value	Odds ratio and 95% CI	Relative weight
	OR	95% CI	Events (total)	Events (total)			
Maron 1996	3	0.078	115/33	2 (2)	0.555		28.55
Kim 2012	21.85	1.12	423/48	3 (3)	0.041		38.18
Gerardin 2014	0.48	0.01	12/52	0 (3)	0.666		33.27
	3.49	0.36	33.67	5 (8)	0.279		

Heterogeneity: $I^2 = 30\%$
Egger's regression test for publication bias argument: $P = 0.62$

Lethality according to gender (male vs. female)

Study name	Statistics for each study				P-Value	Odds ratio and 95% CI	Relative weight
	OR	95% CI	Women	Events (total)			
Maron 1996	1.28	0.03	53/51	1 (1)	0.895		39.56
Kim 2012	4.84	0.23	98/96	4 (4)	0.305		60.44
	2.86	0.27	29.91	5 (5)	0.379		

Heterogeneity: $I^2 = 0\%$
Egger's regression test for publication bias argument: not estimable < 3 studies

